Autres langues Biogen Inc.

Actions

BIIB

US09062X1037

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
219,88 ^USD	-1,32%		-3,39%	+24,94%

02/10	Le traitement expérimental de Biogen contre le lupus améliore les symptômes cutanés	RE
02/10	Biogen affirme que le litifilimab montre une efficacité dans de nouvelles données de phase 2 à 52 semaines	MT

Autres langues

02/10	Biogen's experimental lupus drug shows benefit against skin symptoms
02/10	Biogen Says Litifilimab Shows Efficacy in New 52-Week Phase 2 Data
02/10	Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
02/10	Biogen Inc. Announces 52-Week Results From The Phase 2 Part Of The Ongoing AMETHYST Phase 2/3 Study Of Litifilimab In Cutaneous Lupus Erythematosus
23/09	AI-based drug developer Basecamp valued at $800 million after $140 million funding round
23/09	Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street
23/09	Ha llegado el momento de esta compañía del Nasdaq 100
23/09	Valores destacados al cierre del mercado norteamericano
17/09	Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
17/09	Biogen Publishes Phase 3 Pediatric EMPAVELI Data Showing Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3g or Primary IC-MPGN
16/09	Eisai and Biogen Receive Approval for LEQEMBI Pen Subcutaneous Formulation for Early Alzheimer?s Disease in Japan
11/09	Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
11/09	US FDA approves Scholar Rock's muscle weakness drug
11/09	Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
11/09	Valores destacados al cierre del mercado norteamericano
08/09	Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
08/09	Eisai And Biogen Receive Approval For Leqembi Subcutaneous Formulation As Initiation Treatment For Early Alzheimer's Disease In China
04/09	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
04/09	Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
04/09	Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi
04/09	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
03/09	Compañías que se deben tener muy en cuenta por técnico este jueves en Wall Street
03/09	Valores destacados al cierre del mercado norteamericano
01/09	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)